Dosage guide · 10 mg vial

Tirzepatide Dosage Protocol

Dual GIP and GLP-1 receptor agonist

The official Mounjaro label starts at 2.5 mg once weekly for 4 weeks, then moves to 5 mg; later 2.5 mg increases need at least 4 weeks at the current dose. With 2 mL in Peak's 10 mg vial, the concentration is 5 mg/mL, so the 2.5 mg starting amount is 50 U-100 units (0.5 mL).

How oftenOnce weekly

Starting dose2.5 mg

Start = units50 units

Mix2 mL BAC water

Reviewed 25 Oct 2026 · Education only, not medical advice

Tirzepatide 10 mg vial

View on Peak Peptides

Exact Peak Peptides Australia product photo

Dosage chart How to mix Supplies Calculator About Tirzepatide References

01 · DOSAGE CHART

Tirzepatide dosage chart

Official weekly step-up · 10 mg vial + 2 mL BAC water

BAC water added

Concentration5 mg/mL

1 unit (U-100)50 mcg= 0.01 mL

How oftenOnce weeklySubcutaneous injection

Peak's 10 mg listing highlights a 2 mL final volume, giving 5 mg/mL and 20 U-100 units per 1 mg.

Tirzepatide dosage chart for a 10 mg vial mixed with 2 mL of bacteriostatic water
Week	Weekly dose	Syringe units
Weeks 1–4Start	2.5 mg	50 units0.5 mL
Weeks 5–8Maintenance	5 mg	100 units1 mL
Weeks 9–12	7.5 mg	150 units1.5 mL · 2 syringe draws
Weeks 13–16Maintenance	10 mg	200 units2 mL · 2 syringe draws
Weeks 17–20	12.5 mg	250 units2.5 mL · 3 syringe drawsMore than one 10 mg vial
Week 21 onwardsMax	15 mg	300 units3 mL · 3 syringe drawsMore than one 10 mg vial

Once weekly · same day each week · subcutaneous injection

After week 4, only increase by 2.5 mg after at least 4 weeks at the current amount when prescribed.

The Australian PI lists 5 mg, 10 mg and 15 mg as maintenance amounts; 2.5 mg, 7.5 mg and 12.5 mg are not maintenance amounts.

This chart follows the approved Mounjaro label for tirzepatide; Peak's 10 mg research vial is not a branded regulated medicine. Education only, not medical advice. Dose amounts follow Mounjaro prescribing information: recommended dosage and escalation (DailyMed / Eli Lilly); units are recalculated for the vial and mix selected above.

02 · HOW TO MIX

Mixing a 10 mg vial with 2 mL of BAC water

Using a 1 mL (100-unit) insulin syringe, 2 full draws of bacteriostatic water gives 5 mg/mL.

1
Add the water slowly
Wipe both rubber stoppers with an alcohol swab and let them dry. Draw 2 mL of bacteriostatic water and let it run slowly down the inside of the vial wall — not straight onto the powder.
2
Swirl gently
Swirl or roll the vial gently until the powder has dissolved. Give it a few minutes to settle if needed.
3
Don't shake it
Shaking can damage the peptide and cause foaming. Gentle swirling only.
4
Check it's fully clear
Only use it once it is fully clear with no particles. Label the vial with the date and 5 mg/mL, then store it in the fridge at 2–8 °C.

Full illustrated reconstitution guide

03 · SUPPLIES NEEDED

What you'll need

Counts follow the dosage chart above at the highest amount in each step, using a 10 mg vial mixed with 2 mL.

Length of protocol

1Tirzepatide 10 mg vial10 mg needed in total

51 mL insulin syringesU-100, 27–31G · one per draw + one per vial mixed

1BAC water 10 mL bottle2 mL used for mixing

10Alcohol swabsSkin + stopper, every time

Plus an approved sharps container. Syringes and swabs are sold by Australian pharmacies — Peak Peptides and Pure Performance supply the bacteriostatic water.

Tirzepatide 10 mg vialPeak Peptides Australia

Peak Peptides Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPeak Peptides Australia

Pure Performance Australia Bacteriostatic water 10 mL

Bacteriostatic water 10 mLPure Performance Australia

04 · CALCULATOR

Check a different amount

Enter your vial, water and dose to see the matching syringe units.

Concentration Calculator

Labelled Vial Amount (mg)

Verified Final Liquid Volume2 mL

Amount to Evaluate (not a recommendation)

Concentration

5.00 mg/mL

(5000 mcg/mL)

Calculated Liquid Volume

0.500 mL

Equivalent U-100 volume scale position

50markings (not biological IU)

Illustration of a U-100 volume scale, not preparation or injection guidance

05 · PROTOCOL DETAILS

About Tirzepatide

Protocol overview

Starting amount: 2.5 mg once weekly for weeks 1–4
How it increases: 5 mg after 4 weeks, then optional 2.5 mg increases after at least 4 weeks at the current amount
Frequency: Once weekly
When to take it: Any time of day, with or without meals
Maintenance amounts: 5 mg, 10 mg or 15 mg once weekly; the adult maximum is 15 mg
Common mix: 2 mL BAC water → 5 mg/mL; 2.5 mg = 50 U-100 units (0.5 mL)

Storage

Before mixing: Protect the dry research vial from light and follow the product documentation supplied for the actual material.
After mixing: Peak's BAC-water handling guide says to keep the vial upright, dark and refrigerated at 2–8 °C for about 4 weeks.
Never: Do not freeze a mixed vial or use a solution that is cloudy or contains visible particles.

How it works

Tirzepatide is a dual GIP and GLP-1 receptor agonist. Its C20 fatty-diacid side chain enables albumin binding, which prolongs its half-life.

The Mounjaro label says tirzepatide enhances first- and second-phase insulin secretion and reduces glucagon in a glucose-dependent way. It also delays gastric emptying, lowers food intake and reduces fasting and post-meal glucose concentrations.

Illustrated mechanism explainer

What the research shows

In Australia, the TGA says Mounjaro, which contains tirzepatide, has approval for type 2 diabetes and chronic weight management.
The official adult Mounjaro label starts at 2.5 mg subcutaneously once weekly and permits 2.5 mg increases after at least 4 weeks on the current amount, up to 15 mg once weekly.
In SURMOUNT-1, 2,539 adults without diabetes received tirzepatide 5 mg, 10 mg or 15 mg weekly or placebo for 72 weeks. Mean body-weight change was −15.0%, −19.5% and −20.9% with tirzepatide versus −3.1% with placebo.
In that 72-week trial, 50% of the 10 mg group and 57% of the 15 mg group achieved at least 20% body-weight reduction, compared with 3% of the placebo group.

Reported side effects

The Mounjaro label lists nausea, diarrhoea, decreased appetite, vomiting, constipation, dyspepsia and abdominal pain as common adverse reactions reported in at least 5% of treated patients.
Acute pancreatitis has been observed with Mounjaro and other GLP-1 receptor agonists; the Australian PI also warns that gastrointestinal effects can lead to dehydration and worsening kidney function.
In adult placebo-controlled Mounjaro trials, acute gallbladder disease was reported in 0.6% of Mounjaro-treated patients and 0% of placebo-treated patients.
In SURMOUNT-1, gastrointestinal events were the most common adverse events, mostly mild to moderate and occurring mainly during dose escalation.

Important notes

Mounjaro is a TGA-approved tirzepatide medicine for type 2 diabetes and chronic weight management. Peak's 10 mg listing is in-vitro research material, not a branded regulated medicine.
The Mounjaro label has a boxed warning for thyroid C-cell tumours observed in rats; human relevance is unknown. It is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
For sport, WADA's 2026 Monitoring Program says its substances are not on the Prohibited List and includes markers of tirzepatide for monitoring in and out of competition.
Never use a mixed vial that is cloudy or has particles in it.

Injection basics

Use a new sterile 1 mL (100-unit) U-100 insulin syringe, 27–31G, every time — never reuse or share.
Wipe the vial stopper and the skin with an alcohol swab and let both dry first.
Inject under the skin (subcutaneously) of the abdomen, thigh or upper arm, and rotate sites.
Put used syringes straight into an approved sharps container — the NDSS lists Australian disposal options.

Guidance: World Health Organization · National Diabetes Services Scheme (NDSS)

06 · QUICK ANSWERS

Tirzepatide questions

How many units is 2.5 mg of tirzepatide in a 10 mg vial?

With the default 2 mL mix, the 10 mg vial is 5 mg/mL. A 2.5 mg amount is 0.5 mL, which is 50 units on a U-100 syringe.

How much BAC water is used for Peak's tirzepatide 10 mg vial?

Peak's listing highlights a 2 mL final-volume option. For a 10 mg vial, 10 mg ÷ 2 mL = 5 mg/mL; at that concentration, 1 mg is 0.2 mL or 20 U-100 units.

Why do higher tirzepatide amounts need more than one syringe draw?

At 5 mg/mL, 5 mg is 1 mL or 100 U-100 units. The 7.5 mg, 10 mg, 12.5 mg and 15 mg chart amounts equal 1.5 mL, 2 mL, 2.5 mL and 3 mL, or 150, 200, 250 and 300 U-100 units total.

How long does a 10 mg tirzepatide vial last?

A 10 mg vial contains four 2.5 mg weekly amounts, so it lasts 4 weeks at the starting amount. It contains two 5 mg weekly amounts, so it lasts 2 weeks at 5 mg; 7.5 mg leaves 2.5 mg after one full amount, while 10 mg uses one full vial.

07 · SOURCES